Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT06890598
Trial Phases:	Phase III	Protocol IDs:	18763 (primary) NCI-2025-04391 2024-512302-25-00 J3M-MC-JZQH
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Eli Lilly and Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT06890598

Summary

The main purpose of this study is to assess if olomorasib in combination with
pembrolizumab is more effective than the pembrolizumab and placebo combination in part A
in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in
combination with durvalumab is more effective than the durvalumab and placebo combination
in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer.
The study may last up to 3 years for each participant.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.